On this page you can find relevant researchs on drug-related health topics, including HIV, hepatitis C, drug and overdose prevention, harm reduction and drug treatment. You can also find our Clinical Guidelines.

Morbidity and Mortality
A systematic review of studies from high income countries with large databases of people experiencing homelessness, sex working, contact with criminal justice or drug treatment services. The chances of dying in any given year (Standardised Mortality Ratios) are 8 times higher than average for men and 12 times higher for women. Shocking figures from extremes of social exclusion.
What works?
Inclusion Health is defined, and an evidence synthesis demonstrates that we know how to deliver health care systems that can tackle complexity and multiple morbidity. Multi-disciplinary, multi-agency and multi-component care, taken to the people and centred on building trusting relationships has an international evidence base.
World AIDS Day takes place on the 1st December each year. It’s an opportunity for people worldwide to unite in the fight against HIV, to show support for people living with HIV, and to commemorate those who have died from an AIDS-related illness. Founded in 1988, World AIDS Day was the first ever global health day.
Addressing the specific needs of women who inject drugs
Practical guide for service providers on gender-responsive HIV services
Evidence review summary: drug demand reduction, treatment and harm reduction
Background paper commissioned by the EMCDDA for Health and social responses to drug problems: a European guide
Women who use drugs: Issues, needs, responses, challenges and implications for policy and practice
Background paper commissioned by the EMCDDA for Health and social responses to drug problems: a European guide
Reducing opioid-related deaths
Key periods of increased risk follow periods of abstinence when tolerance is lost, particularly on leaving prison or abstinence-based treatment.
Heroin Assisted Treatment: the case for expanding uptake
Dr Alex Wodak writes for the October 2017 IDHDP Newsletter
Restrictions on free DAA access in many European countries contrary to guidelines and undermine HCV elimination targets, say researchers
The restrictions which many European countries impose on free/reimbursed access to hepatitis C virus (HCV) direct-acting antivirals (DAAs) are contrary to guidelines and undermine the World Health Organization (WHO) goal to eliminate HCV as a major public health concern, new research suggests.
Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review
Sharing of equipment used for injecting drug use (IDU) is a substantial cause of disease burden and a contributor to blood-borne virus transmission. We did a global multistage systematic review to identify the prevalence of IDU among people aged 15–64 years; sociodemographic characteristics of and risk factors for people who inject drugs (PWID); and the prevalence of HIV, hepatitis C virus (HCV), and hepatitis B virus (HBV) among PWID.
Share this on: